ScripLykos Therapeutics , still reeling from US Food and Drug Administration rejection of the company’s capsule formulation of the psychedelic drug midomafetamine for the treatment of post-traumatic stress
ScripHaving an approved and marketed drug is not enough to keep a biopharmaceutical company alive in the current financing environment in which stock prices are down and public offerings are not viable fun
ScripThe market for initial public offerings by biopharmaceutical companies declined to just 22 IPOs in the US in 2022 and it has gotten off to a slow start in 2023 with just three small offerings to date,
ScripThe Dutch firm argenx N.V. closed a follow-on public offering (FOPO) in the US and concurrent private placement of ordinary shares in Europe on 4 February that grossed $1.15bn to fund the company’s